BILLINGS, Montana – All American Pharmaceutical & Natural Foods Corporation (AAP) today announced a significant step forward in the scientific validation of its proprietary carbohydrate, KarboLyn®. The upcoming 2014 clinical study will be led by Dr. Thomas Harman, a former chairman of the Family Medicine Department at the prestigious Mayo Clinic in Rochester, Minnesota.
The study, titled “A Placebo-Controlled Double-Blind Pilot Study: Blood Sugar Response to KarboLyn® or a Glucose Drink during Aerobic Activity,” will examine how this novel homopolysaccharide mixture affects glucose response in both normal and pre-diabetic adults during aerobic exercise.
Why This Matters: The Pre-Diabetes Challenge
According to the National Diabetes Education Program, in conjunction with the National Institutes of Health (NIH), approximately 79 million adults aged 20 and older in the United States have pre-diabetes—a condition that significantly increases the risk of developing type 2 diabetes. Research has consistently shown that lifestyle interventions, including weight loss and increased physical activity, can prevent or delay the progression from pre-diabetes to diabetes.
This study explores whether KarboLyn® may play a supportive role in that equation.
From Elite Athletics to Broader Applications
KarboLyn® was initially developed with a specific purpose: to help elite athletes effectively load muscle glucose before workouts and avoid the energy “burn-out” or “crash” often associated with high-intensity aerobic activity. Its unique molecular structure allows it to behave differently from standard sugar solutions, providing sustained energy without the sharp spikes and drops.
“We already know KarboLyn® behaves somewhat differently than the standard ‘sugar solution’ when consumed by normal adults before athletic workouts,” explained Jeff Golini, CEO and executive scientist at All American Pharmaceutical. “In addition to examining glucose response in normal individuals during aerobic activity, this research will tell us whether KarboLyn® may also have a unique and beneficial impact on pre-diabetics—opening the door to entirely new applications.”
World-Class Scientific Leadership
The involvement of Dr. Thomas Harman underscores the seriousness of this research. As a former chairman of the Family Medicine Department at the Mayo Clinic, Dr. Harman brings decades of clinical expertise and a rigorous, evidence-based approach to the study design and interpretation. His leadership ensures that the resulting data will meet the highest standards of medical credibility.
The study is scheduled to be fielded in summer 2014, with healthy and pre-diabetic adults participating in the controlled trial.
A Commitment to Research and Innovation
This clinical study is just one part of All American Pharmaceutical’s broader commitment to advancing nutritional science.
“We are committed to more research and development in the coming months and years,” said Golini. “Our pipeline of products is strategically poised to impact a number of fields in the 21st century. We are slowly ramping up research geared toward examining the impact of our proprietary products on various physiological conditions—from the athletic industry to healthcare.”
Golini noted that the definition of an “athlete” has expanded considerably in recent years. “Today’s athletes come in all shapes and physiological types. We want to know how our products are going to impact a broad range of users.”
What This Means for Brand Partners
For the brands we manufacture for, this research offers tangible benefits:
| Benefit | Why It Matters |
|---|---|
| Scientific Validation | Peer-reviewed, clinically sound data you can use to support your marketing claims. |
| Credible Leadership | Research led by a former Mayo Clinic physician adds instant authority. |
| Expanded Applications | As we uncover new benefits, your product lines can grow with the science. |
| Trust and Transparency | Partnering with a company that invests in research means you’re building on a foundation of proof, not promises. |
Looking Ahead
As the summer 2014 study gets underway, All American Pharmaceutical remains focused on its core mission: turning raw materials into supplements that build trust, loyalty, and lasting success for our brand partners. With world-class scientific leadership and a pipeline of innovative products, we’re not just keeping pace with the industry—we’re helping to shape its future.
If you’re ready to build your next best seller with a partner committed to science-backed innovation, let’s talk.
